Episode
How NADAC, WAC, and ASP Shape Drug Costs
Summary An in-depth exploration of drug pricing, including key databases like NADAC, WAC, and ASP, and how they influence the ...
The Hidden Costs Employers Don’t See in Traditional Health Plans
Most employers are unknowingly steering their health plans toward higher costs and reduced control — until they understand how fiduciary ...
The Impact of COVID-19 on Patient Trust
In this episode of the Daily Remedy Podcast, Tiffany Ryder discusses her insights on healthcare messaging, the impact of COVID-19 ...
Debunking Myths About GLP-1 Medications
This conversation focuses on debunking myths surrounding GLP-1 medications, particularly the misinformation about their association with pancreatic cancer. The speaker ...
The Future of LLMs in Healthcare
In this episode, the host discusses the significance of large language models (LLMs) in healthcare, their applications, and the challenges ...
The Future of Healthcare Consumerism
Summary In this episode of the Daily Remedy Podcast, the host delves into the evolving landscape of healthcare consumerism as ...
Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer
Summary In this episode of the Daily Remedy Podcast, Dr. Jeffrey Singer discusses his book 'Your Body, Your Health Care,' ...
The cost structure of hospitals nearly doubles
Summary This episode of the Daily Remedy Podcast explores the significant impact of geopolitical conflicts, particularly in the Middle East, ...
The Fight Against Healthcare Fraud: Dr. Rafai’s Story
Summary In this episode of the Daily Remedy Podcast, Dr. Muhammad Ali Rafai shares his harrowing experience of being indicted ...
Navigating the Medical Licensing Maze
Summary In this episode of the Daily Remedy Podcast, Dr. Mark Ibsen shares his harrowing journey through the challenges of ...
The Alarming Truth About Health Insurance Denials
Summary In this episode of the Daily Remedy Podcast, the host discusses the alarming rates of health insurance claim denials, ...
The Importance of NIH Grants
Summary In this episode, the host discusses the critical role of NIH SBIR grants in healthcare innovation and commercialization. The ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read morePopular
-
National Opioid Settlement Injunction
-
Strategies for Transitioning Off GLP-1 Injections
-
Biosimilar Economics Through a Benchmark Lens: What WAC and NADAC Reveal About Competition
-
PBMs as Price Signal Absorbers: How Formulary Architecture Distorts Benchmark Data
-
The IRA’s Negotiation Mechanism and What Benchmark Data Will Reveal About Its Actual Effect
